Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2013

View Archived Issues

Research indicates 1-dSLs as novel clinically relevant biomarkers of metabolic syndrome, diabetes

Vaccination with GI-13020 induces T-cell responses in mice

Portola Pharmaceuticals presents first-in-human results for PRT-064445

Redx Pharma licenses anticancer program from Pharmascience

Tauriga Sciences and Constellation Diagnostics to establish joint venture

Gilead Sciences profiles pipeline developments of first quarter 2013

Antibody-drug conjugate IMGN-289 targets EGFR in cancer cells

GSK profiles novel PERK inhibitor

Incyte Corp. presents new PKA and Akt inhibitors

Bristol-Myers Squibb designs new agents for thromboembolic disorders

Arena Pharmaceuticals prepares novel GPR119 receptor agonists

AbbVie obtains FDA breakthrough therapy designation for combination antiviral therapy

Data safety monitoring committee recommends completion of phase IIb aldoxorubicin trial

New serotonin receptor antagonists synthesized by UCB

Isis Pharmaceuticals begins phase Ib/IIa study of ISIS-STAT3Rx in liver cancer

Senesco begins cohort 3 in study of SNS01-T

Pfizer patents new autotaxin inhibitors

Osphena now available in U.S. pharmacies

Cadila Healthcare discloses novel JAK inhibitors

Kowa applies for approval to conduct phase I study of K-912

Allegro Ophthalmics presents first-in-human results for ALG-1001

Eisai submits European application to expand use of Halaven

Phase II study of RaQualia's acid pump antagonist begins in Korea

Concert Pharmaceuticals and Celgene form collaboration to develop deuterium-modified compounds

Array BioPharma describes planned global phase III trial of MEK-162

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
SKL-35501 shows broad antitumor activity in solid tumors
BioWorld Science
Neurotensin receptor 1 (NTSR1) is overexpressed in several aggressive solid tumors, including colorectal and pancreatic cancer, making it a promising therapeutic...